Literature DB >> 6776195

Human killer cells and natural killer cells: distinct subpopulations of Fc receptor-bearing lymphocytes.

M E Neville.   

Abstract

Unstimulated human peripheral blood lymphocytes were depleted of K cells, which mediate antibody-dependent cellular cytotoxicity (ADCC) without removing NK cells, which mediate natural killing (NK). K cell depletion was achieved by buoyant centrifugation removal of lymphocytes that bound to glutaraldehyde-treated P815-AB cells at high lymphocyte-to-target ratios. Likewise, NK cells were removed with glutaraldehyde-treated K562 cells without removing K cells. Furthermore, both cytotoxic cell populations were observed directly in one agarose single-cell cytotoxic assay (ASCA) using P815-AB and K562 cells simultaneously as target cells. Moreover, the percentage of total cytotoxic cells was equal to the sum of the percentage of K and NK cells observed in separate ASCA. Collectively, these results indicate that K cells and NK cells are distinct subsets of FcR-bearing lymphocytes. One subset, K cells, has more avid Fc receptors (fcR) than NK cells and are 'activated' via thier FcR to kill antibody-coated target cells. The second subset, NK cells, have less avid FcR and are not 'activated' through their FcR to kill antibody-coated target cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776195

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients.

Authors:  R Giacomelli; A Passacantando; G Frieri; I Parzanese; S D'Alò; P Vernia; M T Pimpo; C Petrucci; R Caprilli; M G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Characterization with monoclonal antibodies of human lymphocytes active in natural killing and antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells.

Authors:  I Kurane; D Hebblewaite; F A Ennis
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

4.  A comparison of membrane markers on rat cytotoxic cells.

Authors:  D A Cantrell; R A Robins; R W Baldwin
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

5.  Separation of natural and antibody-dependent cytotoxicity by differential reactivity of human mononuclear cell Fc receptors with IgG.

Authors:  C J Froelich; A D Bankhurst
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

6.  Divergence in activation by poly I:C of human natural killer and killer cells.

Authors:  B S Edwards; E C Borden; K Smith-Zaremba
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Antibody- and interferon-dependent killer cells are part of the NK cell receptor positive subpopulation of human peripheral blood cells.

Authors:  M Ullberg; M Jondal
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

8.  Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis.

Authors:  J H Dobloug; O Førre; T K Kvien; T Egeland; M Degré
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

9.  Cell-mediated immunity and immune complexes in the pathogenesis of type 1 (insulin-dependent) diabetes.

Authors:  P Pozzilli; U Di Mario; D Andreani
Journal:  Acta Diabetol Lat       Date:  1982 Oct-Dec

10.  Natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities can be differentiated by their different sensitivities to interferon and prostaglandin E1.

Authors:  J E Merrill
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.